论文部分内容阅读
目的探讨HA方案治疗老年人急性非淋巴细胞白血病 (ANLL)的疗效及毒副作用。方法随访分析 2 6例老年人ANLL应用HA方案治疗的完全缓解 (CR)率、生存期及药物的毒副作用。并与同期使用小剂量阿糖胞苷 (LDAra C)治疗 2 1例老年人ANLL进行比较。结果HA方案化疗组CR率为 4 2 .3% ,总有效为 5 0 % ,CR后巩固治疗者生存期明显长于CR后未再继续化疗者 (t=3.0 5 0 5 ,P <0 .0 5 )。LDAra C组CR率为 14 .3% ,总有效率为 2 3.8%。两组CR率比较 ,差异有显著性 (χ2 =4 .36 ,P <0 .0 5 )。两种治疗方案的骨髓抑制率和治疗相关死亡无显著性差异 (χ2 =0 .6 1,P>0 .0 5 )。结论HA方案可作为目前较理想的一线联合化疗方案。
Objective To investigate the efficacy and side effects of HA regimen in the treatment of acute non-lymphocytic leukemia (ANLL) in the elderly. Methods The complete remission (CR) rate, survival and drug side effects of ANLL with HA regimen in 26 elderly patients were analyzed retrospectively. And compared with the same period using low dose of cytarabine (LDAra C) treatment of 21 elderly ANLL. Results The response rate of HA regimen to chemotherapy group was 42.3% with a total effective rate of 50%. The survival rate of patients with post-CR consolidation therapy was significantly longer than that without CR after chemotherapy (t = 3.05 05, P <0. 0 5). LDAra C group CR rate of 14.3%, the total effective rate of 23.8%. CR rate of the two groups, the difference was significant (χ2 = 4.36, P <0.05). There was no significant difference in the rates of myelosuppression and treatment-related death between the two treatment regimens (χ2 = 0.61, P> 0.05). Conclusion HA regimen can be regarded as the ideal first-line combination regimen.